期刊
FUTURE ONCOLOGY
卷 15, 期 22, 页码 2657-2666出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0857
关键词
mRCC; patient-reported outcomes; quality of life; TKIs
类别
资金
- Novartis Farma, Origgio, Italy
Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据